SJEPD001535_R1.RNA-Seq
EPN · Posterior Fossa EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Posterior Fossa EPN
- cancer_type
- EPN
- subtype
- Posterior Fossa EPN
- e1_e2
- E2
- umap1_2d
- -5.102412327
- umap2_2d
- -1.053397974
- umap1_3d
- -0.16971258
- umap2_3d
- 2.448884954
- umap3_3d
- 0.78991492
- dataset
- EPN-StJude
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.570
- INTERFERON_ALPHA_RESPONSE+0.550
- HYPOXIA+0.470
- IL6_JAK_STAT3_SIGNALING+0.470
- INTERFERON_GAMMA_RESPONSE+0.460
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.350
- INFLAMMATORY_RESPONSE+0.320
- MYOGENESIS+0.320
- GLYCOLYSIS+0.300
- COAGULATION+0.270
Top 10 suppressed
- PROTEIN_SECRETION-0.460
- OXIDATIVE_PHOSPHORYLATION-0.370
- ANDROGEN_RESPONSE-0.280
- E2F_TARGETS-0.270
- G2M_CHECKPOINT-0.270
- MITOTIC_SPINDLE-0.250
- BILE_ACID_METABOLISM-0.220
- UV_RESPONSE_DN-0.190
- ADIPOGENESIS-0.170
- HEME_METABOLISM-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD001518_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.894 |
| 2 | BS_WWKNJSJ5 | ATRT | — | 0.854 |
| 3 | BS_J8VX4D17 | EPN | Posterior Fossa EPN | 0.846 |
| 4 | 02faba9d-8eda-4967-995d-61a0c13b843c | — | — | 0.846 |
| 5 | SJEPD001508_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.845 |
| 6 | BS_6H1C1ME9 | Posterior Fossa Ependymoma | — | 0.841 |
| 7 | SJEPD034_D.RNA-Seq | EPN | Supratentorial EPN | 0.840 |
| 8 | BS_J8VX4D17 | Posterior Fossa Ependymoma | — | 0.837 |
| 9 | SJEPD001506_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.832 |
| 10 | X41226e40.d143.43b1.ac92.023809990077 | — | cohortA1 | 0.832 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.570 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.550 | Inavolisib | — uncovered |
| HYPOXIA | 0.470 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.470 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.460 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.350 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.320 | Idelalisib | — uncovered |
| MYOGENESIS | 0.320 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.300 | Inavolisib | — uncovered |
| COAGULATION | 0.270 | Binimetinib | — uncovered |
| ANGIOGENESIS | 0.260 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.260 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.260 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.250 | Inavolisib | — uncovered |
| APOPTOSIS | 0.250 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.250 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.220 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.200 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.200 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.190 | Inavolisib | — uncovered |